Plant Virus Trains Immune System to Kill Cancer
Plant Virus Reprograms Immune System to Hunt Cancer Cells
Table of Contents
Breakthrough Discovery Reveals How CPMV Fights Tumors, Paving Way for Novel Immunotherapy
San Diego, CA – In a meaningful leap forward for cancer immunotherapy, researchers have uncovered the precise mechanisms by which a specific plant virus, Cowpea Mosaic Virus (CPMV), primes the immune system to effectively target and eliminate metastatic tumors throughout the body. This groundbreaking research, published in Nature Communications, not only demystifies CPMV’s unique anti-tumor capabilities but also opens exciting avenues for developing cost-effective and potent cancer treatments.
Unlocking the secrets of CPMV’s Anti-Tumor Power
While many viruses can trigger immune responses, CPMV stands out for its remarkable ability to stimulate a robust anti-tumor effect. “It is interesting that CPMV but not other plant viruses stimulates an anti-tumor response,” stated Nicole Steinmetz, the Leo and Trude Szilard Chancellor’s Endowed Chair in the Aiiso Yufeng Li family Department of Chemical and nano Engineering at the UC San Diego Jacobs School of Engineering and the study’s corresponding author.
The key to CPMV’s success lies in its interaction with human immune cells. Anthony Omole, a chemical and nano engineering Ph.D. student in Steinmetz’s lab and the study’s first author, explained, “What we found most exciting is that although human immune cells are not infected by CPMV, they respond to it and are reprogrammed towards an activated state, which ultimately trains them to detect and eradicate cancerous cells.”
A Comparative Study: CPMV vs. CCMV
To pinpoint what makes CPMV so effective, the research team conducted a detailed side-by-side comparison with Cowpea Chlorotic Mottle Virus (CCMV), a closely related plant virus that lacks anti-tumor properties.Both viruses form similarly sized nanoparticles and are readily absorbed by human immune cells. however, their internal cellular actions diverge substantially.
CPMV Stimulates Potent Anti-Cancer Interferons
The study revealed that CPMV stimulates type I, II, and III interferons – a class of proteins renowned for their anti-cancer activities. “This is especially interesting because some of the earliest cancer immunotherapy drugs were recombinant interferons,” noted omole. In contrast, CCMV triggers pro-inflammatory interleukins that do not contribute to effective tumor clearance.
RNA Processing and TLR7 Activation: The Crucial Difference
A critical distinction lies in how the viruses’ genetic material, RNA, is processed within mammalian cells.CPMV’s RNA persists longer and is delivered to the endolysosome, were it activates toll-Like Receptor 7 (TLR7). TLR7 is a vital component in initiating antiviral and, crucially, anti-tumor immune responses.CCMV’s RNA, however, fails to reach this critical activation point, explaining its lack of anti-tumor efficacy.
Cost-Effective Production: The Promise of Molecular Farming
Beyond its biological efficacy,CPMV offers a significant advantage as a cost-effective immunotherapy. Unlike many complex and expensive cancer therapies, CPMV can be produced through molecular farming. “It can be grown in plants using sunlight, soil and water,” Omole highlighted, underscoring its potential for widespread accessibility.
Advancing Towards Clinical Trials
The research team is now focused on advancing CPMV towards human clinical trials. “The present study provides vital insights into the mechanism of action of CPMV. We are diligently working toward the next steps to ensure that the most potent lead candidate is selected to achieve anti-tumor efficacy and safety,” Steinmetz affirmed.”This is the time and we are poised to move this work beyond the bench and toward clinical trials.”
this pioneering work was supported by grants from the National Institutes of Health (NIH), the American Cancer Society, the F.M. Kirby Foundation Inc., the Shaughnessy Family Fund for Nano-ImmunoEngineering at UC San Diego, the San Diego Fellowship Fund, the Alfred P. Sloan Foundation’s Minority PhD Program, and the Frederick National Laboratory for Cancer Research.